AUTHORS
Princess Della Della Tsivor, B.A, Meghan Moore, BA2, Madelyn Amoo-Otoo, BA3, Jeramy Botwe, BS4, Morena da Costa, RN5, Yolanda Aguilera, MD6, Margarida Nafeca Muhongo Texeira7, Wilma Cristina Domingos Faustino8, Claudia Gomes Magalhaes Halumbala, RN9, Elizabeth Mateus10, Fortunato Costa11, Eugênia Manuela Alberto Mateus, MD12, Daniel Lobe Café Púcuta13, Christine Briscoe, MSN, RN, MPH14, Jeannine Margolis15, Roxanne Wood16, Amy Webber17, Lydia Musula18, Manpreet Kochhar, MD19, Joshua Raymond Tanzer, PhD20, Patrick T. McGann, MD21
AFFILIATIONS
1 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
2 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
3 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
4 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
5 Hospital Geral dos Cajueiros, Luanda, Angola
6 Hospital Geral dos Cajueiros, Luanda, Angola
7 Hospital Pediatrico David Bernardino, Luanda, Angola
8 Hospital Pediatrico David Bernardino, Luanda, Angola
9 Hospital Geral dos Cajueiros, Luanda, Angola
10 Hospital Pediatrico David Bernardino, Luanda, Angola
11 Hospital Geral dos Cajueiros, Luanda, Angola
12 Hospital Geral dos Cajueiros, Luanda, Angola
13 Hospital Geral dos Cajueiros, Luanda, Angola
14 Brown University Oncology Research Group (BrUOG), Providence, Rhode Island, United States
15 Brown University Oncology Research Group (BrUOG), Providence, Rhode Island, United States
16 Brown University Oncology Research Group (BrUOG), Providence, Rhode Island, United States
17 Brown University Oncology Research Group (BrUOG), Providence, Rhode Island, United States
18 Brown University Health Comprehensive Sickle Cell Center, Providence, Rhode Island, United States
19 Brown University Health Comprehensive Sickle Cell Center, Providence, Rhode Island, United States, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
20 Brown University Health, Providence, Rhode Island, United States
21 Brown University Health Comprehensive Sickle Cell Center, Providence, Rhode Island, United States, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
ABSTRACT
Introduction:
Sickle cell disease (SCD), a common and life-threatening inherited blood disorder, is among the most under-recognized global health problems, with >500,000 affected infants born each year, primarily in sub-Saharan Africa. Despite the tremendous advances in care and treatment of affected individuals in high-income settings, many of these important interventions – including early diagnosis through newborn screening and disease-modifying therapy with hydroxyurea (HU) – are largely unavailable in sub-Saharan Africa. Over the past decade, several high-impact clinical trials have demonstrated the remarkable clinical and laboratory effects of hydroxyurea for children with SCD living across sub-Saharan Africa. Despite this, there have been no studies that examined the impact of SCD on the quality of life of patients and their families living in Africa. This report describes the impact of SCD on an individual and their family’s quality of life before starting and after 12 months of hydroxyurea treatment using data from the Prioritizing Utilization and Safety of Hydroxyurea Using Precision (PUSH-UP, ClinicalTrials.gov NCT05285917) trial in Luanda, Angola.
Methods:
PUSH-UP is a randomized clinical trial of HU for 400 children ages 6 months through 12 years with SCD at Hospital Geral dos Cajueiros in Luanda, Angola. The primary objective of the study is to compare a pharmacokinetic-guided dosing strategy to a weight-based dosing strategy. An exploratory aim is to evaluate the impact of HU on health-related quality of life (HRQOL) for patients and their families. Following informed consent and prior to HU initiation, there is a 3-month run-in period, followed by a 24-month treatment period. After informed consent, the PedsQL SCD Module (age ≥ 2 years) and PedsQL Family Impact Module (FIM) were administered to families and repeated every 12 months during the study. For each survey, participants answered a series of health-related quality of life questions about the frequency of an experience on a scale from 0 to 4 (0 = never to 4 = always). Each PedsQL item was reverse-scored and linearly transformed to a 0-100 scale such that higher scores indicate a higher HRQOL. While there is no widely agreed upon categorization of scores, we utilized the most common: good HRQOL (≥80); mild impairment/intermediate HRQOL (70-79), moderate impairment/poor HRQOL (60-69); and severe impairment/severely poor, clinically concerning HRQOL (<60).
Results:
This analysis includes 399 participants with a complete FIM Module and 363 participants with a complete PedsQL SCD Module, excluding participants who were withdrawn prior to initiation of hydroxyurea and those who were below the validated age of 2 years for the PedsQL SCD Module. At baseline, prior to the initiation of hydroxyurea, overall HRQOL, according to results on the PedsQL SCD Module, was poor with a mean (±SD) score of 62 ± 16 with uniformly demonstrated poor quality of life across most metrics, including the subtopics of pain (50% rated poor or severely poor), impact of pain on life (74% severely poor), pain management(59% severely poor), general worry (55% poor or severely poor), and emotional well-being (61% severely poor). Interestingly, baseline scores were low but less pronounced in categories of treatment trust (77 ± 23) and communicating with others (74 ± 30), which may be explained by trust in the treatment team at Hospital Geral dos Cajueiros. Results from the FIM module similarly demonstrated poor baseline HQOL with an overall FIM score of 64 ± 33, with particularly low scores in the areas of worry (27 ± 26) and emotional well-being (56 ± 28).
Hydroxyurea treatment for 12 months was associated with significant improvement in HRQOL, with mean scores in the normal range for both the SCD (83) and FIM (83) Modules. The most notable improvements in HRQOL subcategory scores included pain (+30), pain impact (+31), worry about clinical sequelae (+20), and emotional well-being (+30).
Conclusions: These data from the PUSHUP trial demonstrate, for the first time, the very poor HRQOL for children with SCD and their families in Angola at baseline and the significant positive benefit of hydroxyurea on their lives. These data support the known clinical and laboratory benefits of hydroxyurea and provide more rationale/support for expanding access to this life-saving medication that will unquestionably change the lives of the millions of African SCD patients and their families.
DISCLOSURES
Princess Della Della Tsivor, B.A: No relevant conflicts of interest to declare.